| Detailed information |
|---|
| CancerLivER ID | 2574 |
| Biomarker | NFIB,GFI1,TAF1,ONECUT1,BTF,andTRIM32 |
| Biomarker Name/Symbol (given in Publication) | NFIB,GFI1,TAF1,ONECUT1,BTF,andTRIM32 |
| Biomolecule | RNAs |
| Subject | Human |
| Degree of Validity | Potential diagnostic marker for HBV-HCCs patients with LC (liver cirrhosis); but not validated on independent datase |
| Experimental Condition | HBV-HCCs patients with LC (liver cirrhosis) vs without LC (liver cirrhosis) |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Upregulated in HBV-HCCs from patients with LC |
| Level of significance | P< 0.05 |
| Source | Tissue |
| PMID | 12771952 |
| Type of Biomarker | Diagnostic |
| Pathway | transcrip- tion |
| Cohort | 45 hepatocellular carcinoma (HCC) samples, we evaluated gene expression in hepatitis B virus-positive and hepatitis C virus-positive HCCs (HBV- and HCV-HCCs) for an association with liver cirrhosis (LC). 14 HBV- and 31 HCV-HCC patients among 14 HBV- HCC patients, eight had pathological LC, and the r |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | (HBV- and HCV-HCCs), HBV-HCCs associated with LC and those not associated with LC. |
| Year of Publication | 2003 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |